[PDF][PDF] Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
J Krönke, RF Schlenk, KO Jensen… - Journal of Clinical …, 2011 - researchgate.net
Journal of Clinical Oncology, 2011•researchgate.net
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study
From the German-Austrian Acute Myeloid Le Page 1 Monitoring of Minimal Residual Disease
in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid
Leukemia Study Group Jan Krönke, Richard F. Schlenk, Kai-Ole Jensen, Florian Tschürtz,
Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Shiva Onken, Karina Eiwen, Marianne
Habdank, Daniela Späth, Michael Lübbert, Mohammed Wattad, Thomas Kindler, Helmut R …
From the German-Austrian Acute Myeloid Le Page 1 Monitoring of Minimal Residual Disease
in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid
Leukemia Study Group Jan Krönke, Richard F. Schlenk, Kai-Ole Jensen, Florian Tschürtz,
Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Shiva Onken, Karina Eiwen, Marianne
Habdank, Daniela Späth, Michael Lübbert, Mohammed Wattad, Thomas Kindler, Helmut R …
Purpose
To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1mut).
researchgate.net